Related Experiment Video
Updated: Mar 20, 2026
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
MONITORING THE EFFICACY OF MONTELUKAST USED IN CHILDREN WITH RISK OF ASTHMA
I Pkhakadze1, N Alavidze1, S Gamkrelidze1
1Akaki Tsereteli State University, faculty of Medicine, Kutaisi; LTD Children's policlinic №3, Kutaisi; Tbilisi State Medical University, Georgia.
Insights
Montelukast, a leukotriene inhibitor, shows positive effects in treating children at risk of bronchial asthma. This study evaluated its impact on pediatric patients, demonstrating its therapeutic potential.
Area of Science:
- Pediatric Pulmonology
- Pharmacology
Background:
- Bronchial asthma is a significant respiratory condition in children.
- Identifying children at risk and evaluating effective treatments is crucial.
Purpose of the Study:
- To assess the efficacy of Montelukast, a leukotriene inhibitor, in pediatric patients with a risk of bronchial asthma.
- To compare treatment outcomes between inhaled glucocorticoid monotherapy and combination therapy with Montelukast.
Main Methods:
- A cohort of 104 children (5-18 years) at risk for bronchial asthma was studied.
- Risk assessment included Peak Expiratory Flow (PEF) and spirometry.
- Patients were grouped based on treatment: inhaled glucocorticoids alone or with Montelukast.
Main Results:
- 47% of patients were identified as high-risk for asthma.
- Montelukast, a selective leukotriene inhibitor, demonstrated a positive influence on asthma treatment.
- Combination therapy showed promising results in managing pediatric asthma.
Conclusions:
- Montelukast is beneficial in treating various forms of asthma in children.
- The study supports the use of Montelukast in pediatric asthma management, particularly in combination therapy.
Abstract:
The aim of the study is to evaluate the effect of Montelukast - leukotriene inhibitor in children population with risk of bronchial asthma. The research was conducted at LTD. Kutaisi Children primary care unit #3. The data were collected from January 2013 till January 2016. 104 patients (5-18 year, 43 girl, 61 boy), with potential risk of bronchial asthma were involved into the research, 47 (45%) patients out of 104 were considered as a real risk for asthma, based on Peak Expiratory Flow (PEF) and spirometry results. Patients with risk of asthma were grouped according to the method of treatment (monotherapy with inhaled glycocorticoid and inhaled glycocorticoid combined with leukotriene inhibitor). Descriptive statistics methods were used to characterize each variable. Our results indicate on positive influence of montelukast - selective leukotrien inhibitor in treatment of children with various forms of asthma.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:30Asthma-IV: Nursing Management
First, in...
01:24Asthma-III: Symptoms and Complications
Classification of Asthma
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.